Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 18804907.
- Also identified by DOI 10.1016/j.eururo.2008.09.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We present a case of previously unresectable lymphadenopathy in a patient with renal cell carcinoma treated with sunitinib. Complete resection of a 15-cm left renal cell carcinoma was initially impossible due to massive retroperitoneal disease and encasement of the great vessels and mesenteric vessels. Residual retroperitoneal disease from a radical nephrectomy was treated with the oral, multitargeted receptor tyrosine kinase inhibitor, sunitinib. Tumour shrinkage following five cycles of treatment allowed uncomplicated complete resection of the lymphadenopathy. Follow-up after 6 mo showed no evidence of disease recurrence.
Medical subject headings
- Antineoplastic Agents
- Carcinoma, Renal Cell
- Indoles
- Kidney Neoplasms
- Lymph Node Excision
- Lymphatic Diseases
- Pyrroles